Table 4. Multivariate Cox analysis for patients with high-risk PCa.
| Risk factors | Overall morality | Cancer-specific morality | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age | |||||||
| ≤55 | 1 | Ref. | 1 | Ref. | |||
| 55–65 | 1.46 | (1.38–1.56) | <0.001 | 1.12 | (1.03–1.23) | 0.014 | |
| 65–75 | 2.5 | (2.35–2.65) | <0.001 | 1.45 | (1.32–1.58) | <0.001 | |
| 76–85 | 4.6 | (4.32–4.9) | <0.001 | 2.15 | (1.95–2.36) | <0.001 | |
| >85 | 8.84 | (8.24–9.48) | <0.001 | 3.76 | (3.36–4.22) | <0.001 | |
| Race | |||||||
| White | 1 | Ref. | 1 | Ref. | |||
| Black | 1.16 | (1.12–1.19) | <0.001 | 1.13 | (1.07–1.19) | <0.001 | |
| Others | 0.75 | (0.71–0.79) | <0.001 | 0.83 | (0.76–0.9) | <0.001 | |
| Marital status | |||||||
| Married | 1 | Ref. | 1 | Ref. | |||
| Unmarried | 1.3 | (1.26–1.35) | <0.001 | 1.34 | (1.26–1.43) | <0.001 | |
| Divorced | 1.38 | (1.34–1.42) | <0.001 | 1.38 | (1.31–1.46) | <0.001 | |
| Risk | |||||||
| A1 | 1 | Ref. | 1 | Ref. | |||
| A2 | 1.71 | (1.64–1.78) | <0.001 | 2.38 | (2.19–2.59) | <0.001 | |
| A3 | 1.8 | (1.74–1.87) | <0.001 | 2.96 | (2.75–3.18) | <0.001 | |
| B1 | 1.82 | (1.7–1.94) | <0.001 | 2.75 | (2.42–3.11) | <0.001 | |
| B2 | 2.06 | (1.98–2.15) | <0.001 | 4.48 | (4.16–4.84) | <0.001 | |
| B3 | 2.67 | (2.56–2.8) | <0.001 | 6.45 | (5.94–7.01) | <0.001 | |
| C | 2.96 | (2.8–3.14) | <0.001 | 7.7 | (7.02–8.45) | <0.001 | |
| Therapy | |||||||
| RP | 1 | Ref. | 1 | Ref. | |||
| EBRT | 1.33 | (1.29–1.38) | <0.001 | 1.15 | (1.08–1.22) | <0.001 | |
| Prostatectomy | 1.44 | (1.36–1.52) | <0.001 | 1.74 | (1.6–1.9) | <0.001 | |
| Radiation | 2.18 | (2.1–2.26) | <0.001 | 2.27 | (2.13–2.43) | <0.001 | |
| COT | 1.89 | (1.75–2.05) | <0.001 | 2.68 | (2.38–3.02) | <0.001 | |
| NDT | 2.28 | (2.05–2.54) | <0.001 | 2.52 | (2.09–3.03) | <0.001 | |
A1: T3–4, PSA ≤20 ng/mL, GS 2–7; A2: T1–2, PSA >20 ng/mL, GS 2–7; A3: T1–2, PSA ≤20 ng/mL, GS 8–10; B1: T3–4, PSA >20 ng/mL, GS 2–7; B2: T3–4, PSA ≤20 ng/mL, GS 8–10; B3: T1–2, PSA ≥20 ng/mL, GS 8–10; C: T3–4, PSA >20 ng/mL, GS 8–10. PCa, prostate cancer; HR, hazard ratio; CI, confidence interval; Ref., reference; RP, radical prostatectomy; EBRT, external beam radiotherapy; COT, combined therapy; NDT, no definitive therapy; PSA, prostate-specific antigen; GS, Gleason score.